High-Dose Chemotherapy Plus Non-Cryopreserved Autologous Peripheral Blood Stem Cell Transplantation Rescue for Patients With Refractory or Relapsed Hodgkin Disease

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 9, 2006, Pages 942-948

  Mabed, Mohamed ^a   Shamaa, Sameh ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

High dose chemotherapy; Non cryopreserved peripheral blood stem cells; Peripheral blood stem cell transplantation; Relapsed Hodgkin disease; Resistant Hodgkin disease

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; METHYLPREDNISOLONE; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; GRAFT FAILURE; HEMATOPOIESIS; HODGKIN DISEASE; HUMAN; INFECTION; MALE; MYELOABLATIVE CONDITIONING; NEUTROPHIL COUNT; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SHORT COURSE THERAPY; STEM CELL MOBILIZATION; THROMBOCYTE COUNT; TIME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CRYOPRESERVATION; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 33747342474     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.05.013     Document Type: Article

References (33)

1. Duggan D.B., Petroni G.R., Johnson J.L., et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease. report of an intergroup trial. J Clin Oncol 21 (2003) 607-614
2. Diehl V., Franklin J., Pfreundschuh M., et al., German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348 (2003) 2386-2395
3. Martin A., Fernandez-Jimenez M.C., Caballero M.D., et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol 113 (2001) 161-171
4. Radman I., Basic N., Labar B., et al. Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience). Ann Oncol 13 (2002) 1650-1655
5. Yahalom J., Gulati S.C., Toia M., et al. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. J Clin Oncol 11 (1993) 1062-1070
6. Josting A., Katay I., Rueffer U., et al. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM). Ann Oncol 9 (1998) 289-295
7. Hwang W.L., Tsai C.S., Jour J.H., Kuo L.H., and Chang Y.M. Autologous peripheral blood stem cell transplantation using simplified procedures for collection and freezing. Zhonghua Yi Xue Za Zhi (Taipei) 62 (1999) 529-535
8. Preti R.A., Razis E., Ciavarella D., et al. Clinical and laboratory comparison study of refrigerated and cryopreserved bone marrow for transplantation. Bone Marrow Transplant 13 (1994) 253-260
9. Kaplan E.L., and Meier P. Non parametric estimation from in complete observations. J Am Stat Assoc 53 (1958) 157
10. Lazarus H.M., Loberiza Jr. F.R., Zhang M.J., et al. Autotransplants for Hodgkin's disease in first relapse or second remission. a report from the Autologous Blood and Marrow Transplant Registry (ABMTR). Bone Marrow Transplant 27 (2001) 387-396
11. Ahmed T., Wuest D., Ciavarella D., et al. Marrow storage techniques. a clinical comparison of refrigeration versus cryopreservation. Acta Haematol 85 (1991) 173-178
12. Sierra J., Conde E., Iriondo A., et al. Frozen vs. nonfrozen bone marrow for autologous transplantation in lymphomas. a report from the Spanish GEL/TAMO Cooperative Group. Ann Hematol 67 (1993) 111-114
13. Seymour L.K., Dansey R.D., and Bezwoda W.R. Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease. Br J Cancer 70 (1994) 526-530
14. Lazarus H.M., Pecora A.L., Shea T.C., et al. CD34+ selection of hematopoietic blood cell collections and autotransplantation in lymphoma. overnight storage of cells at 4 degrees C does not affect outcome. Bone Marrow Transplant 25 (2000) 559-566
15. Ruiz-Arguelles G.J., Lobato-Mendizabal E., Ruiz-Arguelles A., Perez-Romano B., Arizpe-Bravo D., and Marin-Lopez A. Non-cryopreserved unmanipulated hematopoietic peripheral blood stem cell autotransplant program. long-term results. Arch Med Res 30 (1999) 380-384
16. Ruiz-Arguelles G.J., Gomez-Rangel D., Ruiz-Delgado G.J., Ruiz-Arguelles A., Perez-Romano B., and Rivadeneyra L. Results of an autologous noncryopreserved, unmanipulated peripheral blood hematopoietic stem cell transplant program. a single-institution, 10-year experience. Acta Haematol 110 (2003) 179-183
17. Reece D.E., Barnett M.J., Connors J.M., et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 10 (1991) 1871-1879
18. Stuart M.J., Chao N.S., Horning S.J., et al. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. Biol Blood Marrow Transplant 10 (2001) 552-560
19. Chopra R., McMillan A.K., Linch D.C., et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 81 (1993) 1137-1145
20. Argiris A., Seropian S., and Cooper D.L. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. Ann Oncol 11 (2000) 665-672
21. Reece D.E., Connors J.M., Spinelli J.J., et al. Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 83 (1994) 1193-1199
22. Subira M., Sureda A., Martino R., et al. Autologous stem cell transplantation for high-risk Hodgkin's disease. improvement over time and impact of conditioning regimen. Haematologica 85 (2000) 167-172
23. Stiff P.J., Unger J.M., Forman S.J., et al., Southwest Oncology Group. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease. a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 9 (2003) 529-539
24. Nademanee A., Molina A., Fung H., et al. High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin's disease during first partial or complete remission. Biol Blood Marrow Transplant 5 (1999) 292-298
25. Chabner B.A., Myers C.E., Coleman C.N., and Johns D.G. The clinical pharmacology of antineoplastic agents (second of two parts). N Engl J Med 292 (1975) 1159-1168
26. Huitema A.D., Mathot R.A., Tibben M.M., Rodenhuis S., and Beijnen J.H. A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide. J Pharmacokinet Pharmacodyn 28 (2001) 211-230
27. Schmitz N., Gassmann W., Rister M., et al. Fractionated total body irradiation and high-dose VP 16-213 followed by allogeneic bone marrow transplantation in advanced leukemias. Blood 72 (1988) 1567-1573
28. Relling M.V., McLeod H.L., Bowman L.C., and Santana V.M. Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. Clin Pharmacol Ther 56 (1994) 503-511
29. Kohl P., Koppler H., Schmidt L., et al. Pharmacokinetics of high-dose etoposide after short-term infusion. Cancer Chemother Pharmacol 29 (1992) 316-320
30. Newman E.M., Doroshow J.H., Forman S.J., and Blume K.G. Pharmacokinetics of high-dose etoposide. Clin Pharmacol Ther 43 (1988) 561-564
31. Murry D.J., Sandlund J.T., Stricklin L.M., and Rodman J.H. Pharmacokinetics and acute renal effects of continuously infused carboplatin. Clin Pharmacol Ther 54 (1993) 374-380
32. van Warmerdam L.J., Van der Wall E., ten Bokkel Huinink W.W., Schornagel J.H., Beijinen J.H., and Rodenhuis S. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support (PSCS). Proc Am Soc Clin Oncol 14 (1995) A1503
33. Lazarus H.M., Crilley P., Ciobanu N., et al. High-dose carmustine, etoposide and cisplatine and autolgous bone marrow transplantation for relapsed and refractory lymphoma. J Clin Oncol 10 (1992) 1682-1689